A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

A multi-centre observational study of relapsing-remitting multiple sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN66678006

Enrollment

150

Registered

2012-07-26

Start date

2012-06-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis Nervous System Diseases Multiple sclerosis

Interventions

1. Retrospective questionnaire on the patient?s experience of the last relapse 2. Three short health questionnaires 3. Review of medical records over 3 years from the first prescription of a disease-m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with RRMS by 2005 MacDonald criteria 2. Patients initiated on DMT for the first time after 1 January 2008 and at least 36 months before date of screening for inclusion 3. Patients who consent to complete the questionnaire and for their medical records to be reviewed for the purposes of healthcare research 4. Patients who are able to complete the study questionnaires or have a carer who is able and willing to record the patient?s responses to the study questionnaires

Exclusion criteria

Exclusion criteria: 1. Patients who are unwilling or unable to provide patient consent 2. Patients who are unable to complete the study questionnaires themselves and have no appropriate carer able and willing to assist them

Design outcomes

Primary

Measure	Time frame
To describe the number of documented relapses experienced by patients with MS in the first 3 years following DMT initiation	—

Secondary

Measure	Time frame
1. To describe the number of documented relapses experienced by patients with MS in the 3 years following DMT initiation by severity 2. To describe the DMT prescribing patterns in the first three years following DMT initiation 3. To compare clinician-documented and patient-reported relapse symptoms 4. To describe the change in patient contact with health care professionals resulting from relapse 5. To describe the financial impact of a relapse on patients with MS 6. To describe the impact of a relapse on patients? attitudes to DMT	—

Measure

Time frame

1. To describe the number of documented relapses experienced by patients with MS in the 3 years following DMT initiation by severity 2. To describe the DMT prescribing patterns in the first three years following DMT initiation 3. To compare clinician-documented and patient-reported relapse symptoms 4. To describe the change in patient contact with health care professionals resulting from relapse 5. To describe the financial impact of a relapse on patients with MS 6. To describe the impact of a relapse on patients? attitudes to DMT

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026